The Real Reason CGT Programs Struggle to Scale

Why It Matters

Decoupling collection from manufacturing reduces supply‑chain risk and makes large‑scale CGT commercialization financially and operationally viable.

Key Takeaways

• Fresh leukapheresis dominates early CGT development
• Cryopreservation decouples collection from manufacturing, adding flexibility
• Time‑pressured manual steps drive operational variability
• Early standardization limits disruptive changes at scale
• Integrated cryo‑logistics improve predictability and capacity utilization

Pulse Analysis

The scaling bottleneck in cell and gene therapy stems from legacy workflows designed for academic proof‑of‑concept rather than commercial volume. Early programs rely on fresh leukapheresis because it shortens the time to first‑in‑human data, but this approach embeds tight processing windows, manual handoffs, and site‑specific quirks. As patient populations broaden and manufacturing slots become scarce, the lack of buffer time forces teams into reactive problem‑solving, inflating costs and exposing the supply chain to frequent delays.

Transitioning to cryopreserved starting material fundamentally reshapes the supply chain. By removing the immediate countdown between collection and manufacturing, programs gain the ability to schedule patient visits around clinical readiness rather than production constraints. This flexibility supports deliberate capacity planning, reduces idle manufacturing slots, and creates a more consistent input for downstream processes. Coupled with early‑stage standardization—defining handling, storage, and release protocols—cryopreservation enables repeatable, auditable workflows that satisfy both regulatory expectations and investor scrutiny.

Strategically, the move toward frozen material signals maturity to stakeholders. Regulators look for reproducibility across sites, while investors assess execution risk; a decoupled, standardized supply chain delivers both. Integrated partners that combine cryopreservation, biostorage, and logistics further streamline operations, minimizing handoff variability. Companies that anticipate these needs and embed cryopreservation early position themselves to scale efficiently, reduce cost overruns, and accelerate the path from clinical trials to global commercialization.